Bezerra, Evandro, Lupu, Ludmila, de Lima, Marcos, Pfaller, Lena, Neal, Alison, Hajizadeh, Nelly, Zhao, Qiuhong, Beibel, Martin, Chung, Catherine, Lemmens, Myriam, Sim, Austin, Oertli, Mevion, Voorhees, Timothy, Bohnert, Rebecca, Denlinger, Nathan, Gilbart, Yoann, Bontadelli, Lara, Monovich, Laura, Willert, Jennifer, Stover, Daniel, Gao, Jingbo, Li, Li1, Reinker, Stefan, Naumann, Ulrike, Menssen, Hans, Jones, Daniel, Libertini, Silvana and Brammer, Jonathan E. (2025) Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy. Molecular therapy : the journal of the American Society of Gene Therapy, 33 (12). pp. 6033-6040. ISSN 1525-0024

Abstract

A chimeric antigen receptor (CAR)+ CD30+/CD4+ T cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T cell-based therapy. The TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission 2 years after radiotherapy. This is the only CAR+TCL case reported at the Ohio State University James Comprehensive Cancer Center out of 288 patients treated with CAR-T cells.

Item Type:	Article
Keywords:	Humans CD4-Positive T-Lymphocytes Immunotherapy, Adoptive Ki-1 Antigen Lymphoma, T-Cell Receptors, Chimeric Antigen Remission Induction Treatment Outcome
Date Deposited:	03 Mar 2026 00:45
Last Modified:	03 Mar 2026 00:45
URI:	https://oak.novartis.com/id/eprint/57063